Göran Walldius1, Ingmar Jungner. 1. King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden. goran.walldius@astrazeneca.com
Abstract
PURPOSE OF REVIEW: To compare the potential of high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I, the major protein in HDL particles, in predicting cardiovascular risk. Pros and cons for using these risk markers are discussed. RECENT FINDINGS: Both HDL cholesterol and apoA-I are in most clinical conditions antiatherogenic - the higher the values, the lower the cardiovascular risk. Methodological and physiological factors speak in favour of using apoA-I rather than HDL cholesterol as a marker of risk. In prospective risk studies and in lipid-lowering trials it has been shown that the apoB/A-I ratio, which reflects the cholesterol balance between all potentially atherogenic (apoB) and antiatherogenic lipoproteins (apoA-I), is a better risk marker than low-density lipoprotein cholesterol, HDL cholesterol and lipid ratios in predicting cardiovascular risk and response to lipid lowering induced by statins. Practical advantages speak in favour of using apoB and apoA-I - fasting is not needed to analyze and interpret the values of apoB and apoA-I. SUMMARY: New guidelines should be developed in which target values for apoB and apoA-I are defined to enable the use of these new strong risk markers/factors in clinical practice.
PURPOSE OF REVIEW: To compare the potential of high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I, the major protein in HDL particles, in predicting cardiovascular risk. Pros and cons for using these risk markers are discussed. RECENT FINDINGS: Both HDL cholesterol and apoA-I are in most clinical conditions antiatherogenic - the higher the values, the lower the cardiovascular risk. Methodological and physiological factors speak in favour of using apoA-I rather than HDL cholesterol as a marker of risk. In prospective risk studies and in lipid-lowering trials it has been shown that the apoB/A-I ratio, which reflects the cholesterol balance between all potentially atherogenic (apoB) and antiatherogenic lipoproteins (apoA-I), is a better risk marker than low-density lipoprotein cholesterol, HDL cholesterol and lipid ratios in predicting cardiovascular risk and response to lipid lowering induced by statins. Practical advantages speak in favour of using apoB and apoA-I - fasting is not needed to analyze and interpret the values of apoB and apoA-I. SUMMARY: New guidelines should be developed in which target values for apoB and apoA-I are defined to enable the use of these new strong risk markers/factors in clinical practice.
Authors: Stefan Barlage; Carsten Gnewuch; Gerhard Liebisch; Zsuzsanna Wolf; Franz-Xaver Audebert; Thomas Glück; Dieter Fröhlich; Bernhard K Krämer; Gregor Rothe; Gerd Schmitz Journal: Intensive Care Med Date: 2009-08-08 Impact factor: 17.440
Authors: Ana Claudia Gomes Pereira Petisco; Jorge Eduardo Assef; Carlos Alberto de Jesus; Mohamed Hassan Saleh; Jose Eduardo Martins Barbosa; David Costa de Souza Le Bihan; Ibraim Masciarelli França Pinto; Simone Rolim Fernandes Fontes Pedra; Rodrigo Bellio de Mattos Barretto; Amanda Guerra de Moraes Rego Sousa Journal: Int J Cardiovasc Imaging Date: 2016-10-20 Impact factor: 2.357
Authors: Salma Rahim; Hafez Mohammad A Abdullah; Yousaf Ali; Uzma I Khan; Waqas Ullah; Muhammad A Shahzad; Muhammad Waleed Journal: Cureus Date: 2016-12-24
Authors: Justo Sierra-Johnson; Rachel M Fisher; Abel Romero-Corral; Virend K Somers; Francisco Lopez-Jimenez; John Ohrvik; Göran Walldius; Mai-Lis Hellenius; Anders Hamsten Journal: Eur Heart J Date: 2008-08-01 Impact factor: 29.983
Authors: Kyle B Walsh; Kimberly Hart; Susan Roll; Matthew Sperling; Dusten Unruh; W Sean Davidson; Christopher J Lindsell; Opeolu Adeoye Journal: J Stroke Cerebrovasc Dis Date: 2016-03-16 Impact factor: 2.136
Authors: Scott M Gordon; Jonathan H Chung; Martin P Playford; Amit K Dey; Denis Sviridov; Fayaz Seifuddin; Yun-Ching Chen; Mehdi Pirooznia; Marcus Y Chen; Nehal N Mehta; Alan T Remaley Journal: Atherosclerosis Date: 2018-09-25 Impact factor: 5.162